Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Flutamide Euflex, Eulexin 125 mg Hormonal Therapy Androgen Receptor Inhibitor Yes 1989 In Use
NA Estradiol Estrace 0.5mg Hormonal Therapy Estrogen Yes 1998 In Use
J2502 Pasireotide Signifor, Signifor LAR 1 mg Hormonal Therapy Somatostatin Analog No 2012 Jan 1, 2016 In Use
C9454 Pasireotide Signifor, Signifor LAR 1 mg Hormonal Therapy Somatostatin Analog No 2012 Jan 1, 2016 In Use
S0156 Exemestane Aromasin 25 mg Hormonal Therapy Aromatase Inhibitor Yes 1999 Jan 1, 2001 In Use
NA Polyestradiol Phosphate Estradurin, Estradurine 40 mg Hormonal Therapy Estrogen Derivative No 1957 Aug 8, 2003 No Longer Used
NA Cysteamine Bitartrate Procysbi 25mg, 75mg, 300mg Chemotherapy Cystine-Depleting Agent Yes 2013 In Use
J1436 Etidronate Disodium Didronel 300 mg Ancillary Therapy Bisphosphonate No 1977 Jan 1, 1990 In Use
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 0.3 mg Hormonal Therapy Estrogen Yes 1977 In Use
NA Cysteamine Bitartrate Cystagon 50mg, 150mg Chemotherapy Cystine-Depleting Agent Yes 1994 In Use
NA Chlorotrianisene Anisene 12 mg Hormonal Therapy Estrogen Yes 1992 1997 In Use
J2354 octreotide sandostatin 25 mcg Hormonal Therapy Somatostatin Analog No 1998 Jan 1, 2004 In Use
J1380 Estradiol Valerate Delestrogen 10 mg Hormonal Therapy Estrogen No 1954 Jan 1, 1997 In Use
NA Megestrol Acetate Megace 20mg, 40mg Hormonal Therapy Progestin Yes 1988 In Use
J9394 Fulvestrant (Fresnius) Fulvestrant (Fresnius) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
C9098 Ciltacabtagene autoleucel CARVYKTI up to 100 million Immunotherapy CAR-T No 2022 Mar 25, 2022 Sep 27, 2022 No Longer Used
Q2056 Ciltacabtagene autoleucel CARVYKTI up to 100 million Immunotherapy CAR-T No 2022 Sep 27, 2022 In Use
J1050 Medroxyprogesterone Acetate Depo-Provera, Depo-SubQ Provera, Provera 1 mg Hormonal Therapy Progestin No 1959 Jan 1, 2013 In Use
A9607 Lutetium Lu 177 vipivotide tetraxetan PLUVICTO 1 millicurie Radiopharmaceutical Radiopharmaceutical In Use
J0896 Luspatercept Reblozyl 0.25mg Ancillary Therapy Erythropoiesis-Stimulating Agent No 2019 Jul 1, 2020 In Use
NA Trilostane Modrastane 60 mg, 120 mg Hormonal Therapy Adrenocortical suppressant Yes 1984 1994 In Use
J3315 Triptorelin Pamoate Trelstar, Trelstar Mixject 3.75 mg Hormonal Therapy GnRH Agonist No 2000 Jan 1, 2003 In Use
S0187 Tamoxifen Citrate Nolvadex, Nolvadex-D, Soltamox 10 mg Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Yes 1977 Jan 1, 2002 In Use
J1952 Leuprolide Mesylate Camcevi 1mg Hormonal Therapy GnRH Agonist No 2021 Jan 26, 2022 In Use
J9219 Leuprolide Acetate Implant Viadur 65 mg Hormonal Therapy GnRH Agonist No 2000 Jan 1, 2016 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.